These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 29977820)

  • 1. Nanotechnology in retinal drug delivery.
    Jiang S; Franco YL; Zhou Y; Chen J
    Int J Ophthalmol; 2018; 11(6):1038-1044. PubMed ID: 29977820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomedicine and drug delivery to the retina: current status and implications for gene therapy.
    Tawfik M; Chen F; Goldberg JL; Sabel BA
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Dec; 395(12):1477-1507. PubMed ID: 36107200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review on recent drug delivery systems for posterior segment of eye.
    Nayak K; Misra M
    Biomed Pharmacother; 2018 Nov; 107():1564-1582. PubMed ID: 30257375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel approach for management of age-related macular degeneration--antiangiogenic therapy and retinal regenerative therapy].
    Tamaki Y
    Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):232-68; discussion 269. PubMed ID: 17402564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema.
    Wong CW; Wong TT
    Br J Ophthalmol; 2019 Oct; 103(10):1356-1360. PubMed ID: 31040133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Periocular routes for retinal drug delivery.
    Raghava S; Hammond M; Kompella UB
    Expert Opin Drug Deliv; 2004 Nov; 1(1):99-114. PubMed ID: 16296723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal hydrogels for sustained release of therapeutic proteins.
    Ilochonwu BC; Urtti A; Hennink WE; Vermonden T
    J Control Release; 2020 Oct; 326():419-441. PubMed ID: 32717302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posterior Segment Ophthalmic Drug Delivery: Role of Muco-Adhesion with a Special Focus on Chitosan.
    Burhan AM; Klahan B; Cummins W; Andrés-Guerrero V; Byrne ME; O'Reilly NJ; Chauhan A; Fitzhenry L; Hughes H
    Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives.
    Kim HM; Woo SJ
    Pharmaceutics; 2021 Jan; 13(1):. PubMed ID: 33467779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel drug delivery systems for retinal diseases. A review.
    Lee SS; Robinson MR
    Ophthalmic Res; 2009; 41(3):124-35. PubMed ID: 19321933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of lipid nanoparticles to ocular drug delivery.
    Battaglia L; Serpe L; Foglietta F; Muntoni E; Gallarate M; Del Pozo Rodriguez A; Solinis MA
    Expert Opin Drug Deliv; 2016 Dec; 13(12):1743-1757. PubMed ID: 27291069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
    Myles ME; Neumann DM; Hill JM
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal therapeutic nanoparticles for age-related macular degeneration: Design principles, progress and opportunities.
    Zhang Y; Watson S; Ramaswamy Y; Singh G
    Adv Colloid Interface Sci; 2024 Jul; 329():103200. PubMed ID: 38788306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancements in Nanosystems for Ocular Drug Delivery: A Focus on Pediatric Retinoblastoma.
    Wu KY; Wang XC; Anderson M; Tran SD
    Molecules; 2024 May; 29(10):. PubMed ID: 38792122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triamcinolone and intraocular sustained-release delivery systems in diabetic retinopathy.
    Yilmaz T; Cordero-Coma M; Lavaque AJ; Gallagher MJ; Padula WV
    Curr Pharm Biotechnol; 2011 Mar; 12(3):337-46. PubMed ID: 20939800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new era in posterior segment ocular drug delivery: Translation of systemic, cell-targeted, dendrimer-based therapies.
    Kannan RM; Pitha I; Parikh KS
    Adv Drug Deliv Rev; 2023 Sep; 200():115005. PubMed ID: 37419213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Updates on Nanocarriers for Drug Delivery in Posterior Segment Diseases with Emphasis on Diabetic Retinopathy.
    Parashar R; Vyas A; Sah AK; Hemnani N; Thangaraju P; Suresh PK
    Curr Diabetes Rev; 2024; 20(6):e171023222282. PubMed ID: 37855359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic aspects of retinal drug delivery.
    Del Amo EM; Rimpelä AK; Heikkinen E; Kari OK; Ramsay E; Lajunen T; Schmitt M; Pelkonen L; Bhattacharya M; Richardson D; Subrizi A; Turunen T; Reinisalo M; Itkonen J; Toropainen E; Casteleijn M; Kidron H; Antopolsky M; Vellonen KS; Ruponen M; Urtti A
    Prog Retin Eye Res; 2017 Mar; 57():134-185. PubMed ID: 28028001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent perspectives in ocular drug delivery.
    Gaudana R; Jwala J; Boddu SH; Mitra AK
    Pharm Res; 2009 May; 26(5):1197-216. PubMed ID: 18758924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye.
    Bisht R; Jaiswal JK; Rupenthal ID
    Med Hypotheses; 2017 Jun; 103():5-9. PubMed ID: 28571808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.